Jun 3, 2020
June 3, 2020 Kezar Life Sciences, Inc. today announced updated results from the Phase 1b (Ph1b) portion of MISSION, a study testing the safety and tolerability of KZR-616 for people with systemic lupus erythematosus (SLE) and those who also have lupus nephritis. The drug showed effectiveness in improving seven measures of disease activity. Both of […]Read More
Use this tool to search all lupus trials and create a personalized list of studies by the type of lupus you have and where you live.